“We don't actually know how many animals we're testing on in this country, because most of them are not protected by any laws. There's not even a requirement that you track their numbers.” – Delcianna Winders

Today, I have the pleasure of sharing some genuinely promising news. For decades, the FDA and NIH have required or relied on animal testing as the gold standard for drug development and biomedical research. But that's beginning to change.

Both agencies have just announced significant steps to reduce animal testing—moves that could mark a turning point in how science is done. The FDA is beginning to phase out animal testing requirements for certain new drug applications, starting with monoclonal antibody therapies, and is pushing forward the use of more ethical, human-relevant technologies—like organ-on-a-chip systems and advanced computer modeling. At the same time, the NIH is prioritizing human-based approaches and creating a new office dedicated to accelerating the development and adoption of these new methods across biomedical research.

To help us understand what all of this means, what led to these changes, and what still needs to happen, I’m joined by Delci Winders, director of the Animal Law and Policy Institute at Vermont Law and Graduate School. Delci is one of the leading voices at the intersection of law, science, and animal protection—and she’s here to walk us through this historic shift.